Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells

Multiple clinical trials are ongoing to evaluate the potential antitumor activity of human TNF variants, Fas ligand (FasL), TNF-related apoptosis inducing ligand (TRAIL) and its agonistic antibodies. These drug products act through the death receptors (DRs) TNF receptor 1 (TNFR1), Fas/CD95, DR4 (TRA...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jun-Jie, Jennifer Shen, H.-C., Rivera Rosado, Leslie A., Zhang, Yaqin, Di, Xu, Zhang, Baolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2012
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478460/
https://www.ncbi.nlm.nih.gov/pubmed/22909995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478460/
https://www.ncbi.nlm.nih.gov/pubmed/22909995

Ejemplares similares